Bioscience I. 2017 Ltd F2 Sells 29,631 Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Bioscience I. 2017 Ltd F2 sold 29,631 shares of the company’s stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $13.00, for a total value of $385,203.00. Following the completion of the transaction, the insider now owns 537,392 shares in the company, valued at $6,986,096. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ CGEM traded up $0.59 on Thursday, reaching $13.32. The stock had a trading volume of 288,158 shares, compared to its average volume of 401,262. The firm has a market capitalization of $596.51 million, a price-to-earnings ratio of -7.53 and a beta of 0.17. Cullinan Oncology, Inc. has a 12-month low of $7.30 and a 12-month high of $30.33. The stock has a fifty day moving average price of $11.14 and a two-hundred day moving average price of $12.93.

Cullinan Oncology (NASDAQ:CGEM – Get Rating) last announced its earnings results on Monday, May 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.34. On average, sell-side analysts expect that Cullinan Oncology, Inc. will post 3.39 earnings per share for the current year.

Separately, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Cullinan Oncology in a report on Tuesday, May 17th.

Several institutional investors have recently bought and sold shares of the company. Credit Suisse AG increased its position in shares of Cullinan Oncology by 5.6% during the third quarter. Credit Suisse AG now owns 9,534 shares of the company’s stock worth $215,000 after acquiring an additional 503 shares during the period. Rhumbline Advisers increased its position in shares of Cullinan Oncology by 4.7% during the first quarter. Rhumbline Advisers now owns 32,045 shares of the company’s stock worth $336,000 after acquiring an additional 1,445 shares during the period. Citigroup Inc. grew its stake in shares of Cullinan Oncology by 265.7% during the third quarter. Citigroup Inc. now owns 3,171 shares of the company’s stock worth $72,000 after purchasing an additional 2,304 shares in the last quarter. Northern Trust Corp grew its stake in shares of Cullinan Oncology by 1.0% during the fourth quarter. Northern Trust Corp now owns 231,383 shares of the company’s stock worth $3,571,000 after purchasing an additional 2,380 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY grew its stake in shares of Cullinan Oncology by 48.3% during the third quarter. Metropolitan Life Insurance Co NY now owns 7,420 shares of the company’s stock worth $167,000 after purchasing an additional 2,418 shares in the last quarter. 93.62% of the stock is currently owned by institutional investors and hedge funds.

About Cullinan Oncology (Get Rating)

Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

See Also